Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol

Novo Nordisk

Status: Invitation-only

Conditions: Haemophilia A

Treatments: Drug: Turoctocog alfa pegol

Study type: Observational

Funder types: Industry

Identifiers

NCT04682145

NN7088-4557

U1111-1235-5939 (Other Identifier)

Details and patient eligibility

About

This non-interventional study concerns a safety data collection based on adverse event data from a third-party registry (European Haemophilia Safety Surveillance System, EUHASS) that includes information about adverse events from patients with haemophilia A treated with turoctocog alfa pegol. There is no extra burden to the patients by participating in this registry-based data collection.

Enrollment: 50 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participation in the European Haemophilia Safety Surveillance System (EUHASS).

Exclusion criteria

• N/A

Trial design

50 participants in 1 patient group

Haemophilia A patients

Description:

All patients with haemophilia A treated with turoctocog alfa pegol and reporting adverse events to EUHASS.

Treatment:

Drug: Turoctocog alfa pegol